LY3200882

DRUG4 trials

Sponsors

Eli Lilly and Company, The Netherlands Cancer Institute

Conditions

Advanced CancerColorectal Cancer MetastaticHealthySolid Tumor

Phase 1

A Study of LY3200882 in Participants With Solid Tumors

Active, not recruitingNCT02937272

Eli Lilly and CompanySolid Tumor

Start: 2016-11-21End: 2027-08-01Target: 223Updated: 2026-04-03

An Interaction Study of LY3200882 in Healthy Participants

CompletedNCT03792139

Eli Lilly and CompanyHealthy

Start: 2019-01-08End: 2019-02-23Updated: 2019-03-08

LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

WithdrawnNCT04031872

The Netherlands Cancer InstituteColorectal Cancer Metastatic

Start: 2020-01-01End: 2020-01-01Updated: 2025-09-05

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

WithdrawnNCT04158700

Eli Lilly and CompanyAdvanced Cancer

Start: 2019-12-05End: 2023-05-11Updated: 2020-02-19

Related Papers

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Clinical Cancer Research2021-09-2163 citations